Ask
Search
My library
ORKG

ORKG Ask

Our mission is to organize scholarly knowledge and make it accessible to humans and machines.

About

About ORKG Ask
Report issue
Statistics
Contact

Legal

Terms of use
Data protection (sheet)
Imprint
Accessibility
License

Technical

We
open source
System status
Changelog
Frontend: v1.41.0
Backend: v1.13.4

We use cookies to provide a better user experience.

Data Protection

What Evidence is Available on Apixaban for the Primary Prevention of Stroke in Patients with Atrial Fibrillation?

Dang, Justin
Tsu, Laura

Publication date

January 2012

Publisher

Chapman University Digital Commons

Language

English

Abstract

This drug information question and answer sheet discusses the use of apixaban (Eliquis) for the primary prevention of stroke in patients with atrial fibrillation

Extracted data

Topics

thumbnail of dbpedia resource

atrial fibrillationDisease

thumbnail of dbpedia resource

apixabanChemical substance

Related items

Clinical experience with apixaban in atrial fibrillation: implications of AVERROES

Raffaele De Caterina
Correspondence Raffaele
De Caterina

September 2016

Abstract: Atrial fibrillation is an extremely common arrhythmia, which substantially increases the r...

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial

Lopes, R.
Al-Khatib, S.
Wallentin, L.
Yang, H.
Ansell, J.
Bahit, M.
De Caterina, R.
Dorian, P.
Easton, J.
Erol, C.
Ezekowitz, J.
Gersh, B.
Granger, C.
Hohnloser, S.
Horowitz, J.
Hylek, E.
McMurray, J.
Mohan, P.
Vinereanu, D.
Alexander, J.

January 2012

BACKGROUND The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillati...

Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation

Kirchhof, Paulus
Haeusler, Karl Georg
Blank, Benjamin
De Bono, Joseph
Callans, David
Elvan, Arif
Fetsch, Thomas
Van Gelder, Isabelle C.
Gentlesk, Philip
Grimaldi, Massimo
Hansen, Jim
Hindricks, Gerhard
Al-Khalidi, Hussein R.
Massaro, Tyler
Mont, Lluis
Nielsen, Jens Cosedis
Noelker, Georg
Piccini, Jonathan P.
De Potter, Tom
Scherr, Daniel
Schotten, Ulrich
Themistoclakis, Sakis
Todd, Derick
Vijgen, Johan
Di Biase, Luigi

August 2018

Aims It is recommended to perform atrial fibrillation ablation with continuous anticoagulation. Cont...

What Evidence is Available on Apixaban for the Primary Prevention of Stroke in Patients with Atrial Fibrillation?

Dang, Justin
Tsu, Laura

January 2012

This drug information question and answer sheet discusses the use of apixaban (Eliquis) for the prim...

Is Apixaban Effective for the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation?

Moore, Amira

January 2014

OBJECTIVE: The objective of this EBM review is to determine whether or not Apixaban is effective for...

Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation : A Systematic Review and Meta-Analysis

M. Proietti
I. Romanazzi
G.F. Romiti
A. Farcomeni
G.Y.H. Lip

January 2018

Background and purpose: The use of oral anticoagulant therapy for stroke prevention in atrial fibril...

Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis

Proietti, Marco
ROMANAZZI, IMMA
Romiti, Giulio Francesco
Farcomeni, Alessio
Lip, Gregory Y. H.

January 2018

The use of oral anticoagulant therapy for stroke prevention in atrial fibrillation has been transfor...

Apixaban versus warfarin in patients with atrial fibrillation

January 2011

Item does not contain fulltextBACKGROUND: Vitamin K antagonists are highly effective in preventing s...

Apixaban versus Warfarin in patients with atrial fibrillation

Granger, C.
Alexander, J.
McMurray, J.
Lopes, R.
Hylek, E.
Hanna, M.
Al-Khalidi, H.
Ansell, J.
Avezum, A.
Atar, D.
Bahit, M.
Diaz, R.
Easton, J.
Ezekowitz, J.
Garcia, D.
Geraldes, M.
Gersh, B.
Golitsyn, S.
Goto, S.
Hermosillo, A.
et al.

January 2011

BackgroundVitamin K antagonists are highly effective in preventing stroke in patients with atrial fi...

Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.

Lopes, R.D.
Alexander, J.H.
Al-Khatib, S.M.
Ansell, J.
Diaz, R.
Easton, J.D.
Gersh, B.J.
Granger, C.B.
Hanna, M.
Horowitz, J.
Hylek, E.M.
McMurray, J.J.
Verheugt, F.W.A.
Wallentin, L.

January 2010

Contains fulltext : 88254.pdf (publisher's version ) (Closed access)Atrial fibrill...

Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.

November 2023

BACKGROUND: Subclinical atrial fibrillation is short-lasting and asymptomatic and can usually be det...

Safety and Efficacy of Apixaban in the Treatment of Atrial Fibrillation

Andrew Martin
Ralph Stewart

January 2012

Atrial fibrillation is a common arrhythmia that increases the risk of stroke and systemic embolism. ...

Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale

Lopes, R. D.
Alexander, J. H.
Al Khatib, S. M.
Ansell, J.
Diaz, R.
Easton, J. D.
Gersh, B. J.
Granger, C. B.
Hanna, M.
Horowitz, J.
Hylek, E. M.
McMurray, J. J. V.
Verheugt, F. W. A.
Wallentin, L.

January 2010

Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with vit...

Apixaban for reduction in stroke and other ThromboemboLic events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale

Lopes, R.
Alexander, J.
Al-Khatib, S.
Ansell, J.
Diaz, R.
Easton, J.
Gersh, B.
Granger, C.
Hanna, M.
Horowitz, J.
Hylek, E.
McMurray, J.
Verheugt, F.
Wallentin, L.

January 2010

Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with vit...

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: A secondary analysis of a randomised controlled trial

Lopes, Renato D.
Al-Khatib, Sana M.
Wallentin, Lars
Yang, Hongqiu
Ansell, Jack
Bahit, Maria C.
De Caterina, Raffaele
Dorian, Paul
Easton, J. Donald
Erol, Çetin
Ezekowitz, Justin A.
Gersh, Bernard J.
Granger, Christopher B.
Hohnloser, Stefan H.
Horowitz, John
Hylek, Elaine M.
McMurray, John J. V.
Mohan, Puneet
Vinereanu, Dragos
Alexander, John H.

January 2012

Background: The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillat...

Clinical experience with apixaban in atrial fibrillation: implications of AVERROES

Raffaele De Caterina
Correspondence Raffaele
De Caterina

September 2016

Abstract: Atrial fibrillation is an extremely common arrhythmia, which substantially increases the r...

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial

Lopes, R.
Al-Khatib, S.
Wallentin, L.
Yang, H.
Ansell, J.
Bahit, M.
De Caterina, R.
Dorian, P.
Easton, J.
Erol, C.
Ezekowitz, J.
Gersh, B.
Granger, C.
Hohnloser, S.
Horowitz, J.
Hylek, E.
McMurray, J.
Mohan, P.
Vinereanu, D.
Alexander, J.

January 2012

BACKGROUND The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillati...

Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation

Kirchhof, Paulus
Haeusler, Karl Georg
Blank, Benjamin
De Bono, Joseph
Callans, David
Elvan, Arif
Fetsch, Thomas
Van Gelder, Isabelle C.
Gentlesk, Philip
Grimaldi, Massimo
Hansen, Jim
Hindricks, Gerhard
Al-Khalidi, Hussein R.
Massaro, Tyler
Mont, Lluis
Nielsen, Jens Cosedis
Noelker, Georg
Piccini, Jonathan P.
De Potter, Tom
Scherr, Daniel
Schotten, Ulrich
Themistoclakis, Sakis
Todd, Derick
Vijgen, Johan
Di Biase, Luigi

August 2018

Aims It is recommended to perform atrial fibrillation ablation with continuous anticoagulation. Cont...

What Evidence is Available on Apixaban for the Primary Prevention of Stroke in Patients with Atrial Fibrillation?

Dang, Justin
Tsu, Laura

January 2012

This drug information question and answer sheet discusses the use of apixaban (Eliquis) for the prim...

Is Apixaban Effective for the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation?

Moore, Amira

January 2014

OBJECTIVE: The objective of this EBM review is to determine whether or not Apixaban is effective for...

Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation : A Systematic Review and Meta-Analysis

M. Proietti
I. Romanazzi
G.F. Romiti
A. Farcomeni
G.Y.H. Lip

January 2018

Background and purpose: The use of oral anticoagulant therapy for stroke prevention in atrial fibril...

Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis

Proietti, Marco
ROMANAZZI, IMMA
Romiti, Giulio Francesco
Farcomeni, Alessio
Lip, Gregory Y. H.

January 2018

The use of oral anticoagulant therapy for stroke prevention in atrial fibrillation has been transfor...

Apixaban versus warfarin in patients with atrial fibrillation

January 2011

Item does not contain fulltextBACKGROUND: Vitamin K antagonists are highly effective in preventing s...

Apixaban versus Warfarin in patients with atrial fibrillation

Granger, C.
Alexander, J.
McMurray, J.
Lopes, R.
Hylek, E.
Hanna, M.
Al-Khalidi, H.
Ansell, J.
Avezum, A.
Atar, D.
Bahit, M.
Diaz, R.
Easton, J.
Ezekowitz, J.
Garcia, D.
Geraldes, M.
Gersh, B.
Golitsyn, S.
Goto, S.
Hermosillo, A.
et al.

January 2011

BackgroundVitamin K antagonists are highly effective in preventing stroke in patients with atrial fi...

Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.

Lopes, R.D.
Alexander, J.H.
Al-Khatib, S.M.
Ansell, J.
Diaz, R.
Easton, J.D.
Gersh, B.J.
Granger, C.B.
Hanna, M.
Horowitz, J.
Hylek, E.M.
McMurray, J.J.
Verheugt, F.W.A.
Wallentin, L.

January 2010

Contains fulltext : 88254.pdf (publisher's version ) (Closed access)Atrial fibrill...

Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.

November 2023

BACKGROUND: Subclinical atrial fibrillation is short-lasting and asymptomatic and can usually be det...

Safety and Efficacy of Apixaban in the Treatment of Atrial Fibrillation

Andrew Martin
Ralph Stewart

January 2012

Atrial fibrillation is a common arrhythmia that increases the risk of stroke and systemic embolism. ...

Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale

Lopes, R. D.
Alexander, J. H.
Al Khatib, S. M.
Ansell, J.
Diaz, R.
Easton, J. D.
Gersh, B. J.
Granger, C. B.
Hanna, M.
Horowitz, J.
Hylek, E. M.
McMurray, J. J. V.
Verheugt, F. W. A.
Wallentin, L.

January 2010

Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with vit...

Apixaban for reduction in stroke and other ThromboemboLic events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale

Lopes, R.
Alexander, J.
Al-Khatib, S.
Ansell, J.
Diaz, R.
Easton, J.
Gersh, B.
Granger, C.
Hanna, M.
Horowitz, J.
Hylek, E.
McMurray, J.
Verheugt, F.
Wallentin, L.

January 2010

Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with vit...

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: A secondary analysis of a randomised controlled trial

Lopes, Renato D.
Al-Khatib, Sana M.
Wallentin, Lars
Yang, Hongqiu
Ansell, Jack
Bahit, Maria C.
De Caterina, Raffaele
Dorian, Paul
Easton, J. Donald
Erol, Çetin
Ezekowitz, Justin A.
Gersh, Bernard J.
Granger, Christopher B.
Hohnloser, Stefan H.
Horowitz, John
Hylek, Elaine M.
McMurray, John J. V.
Mohan, Puneet
Vinereanu, Dragos
Alexander, John H.

January 2012

Background: The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillat...

Clinical experience with apixaban in atrial fibrillation: implications of AVERROES

Raffaele De Caterina
Correspondence Raffaele
De Caterina

September 2016

Abstract: Atrial fibrillation is an extremely common arrhythmia, which substantially increases the r...

Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial

Lopes, R.
Al-Khatib, S.
Wallentin, L.
Yang, H.
Ansell, J.
Bahit, M.
De Caterina, R.
Dorian, P.
Easton, J.
Erol, C.
Ezekowitz, J.
Gersh, B.
Granger, C.
Hohnloser, S.
Horowitz, J.
Hylek, E.
McMurray, J.
Mohan, P.
Vinereanu, D.
Alexander, J.

January 2012

BACKGROUND The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillati...

Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation

Kirchhof, Paulus
Haeusler, Karl Georg
Blank, Benjamin
De Bono, Joseph
Callans, David
Elvan, Arif
Fetsch, Thomas
Van Gelder, Isabelle C.
Gentlesk, Philip
Grimaldi, Massimo
Hansen, Jim
Hindricks, Gerhard
Al-Khalidi, Hussein R.
Massaro, Tyler
Mont, Lluis
Nielsen, Jens Cosedis
Noelker, Georg
Piccini, Jonathan P.
De Potter, Tom
Scherr, Daniel
Schotten, Ulrich
Themistoclakis, Sakis
Todd, Derick
Vijgen, Johan
Di Biase, Luigi

August 2018

Aims It is recommended to perform atrial fibrillation ablation with continuous anticoagulation. Cont...